Project Grant R01AI195581
Award Date 7/22/26
Completion Date 6/30/31
Dollars Obligated $679K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38103, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $163,852 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the septation initiation network (SIN) kinase cascade in Aspergillus fumigatus, with the goal of enhancing echinocandin antifungal efficacy against invasive pulmonary aspergillosis. The research interrogates SIDB-dependent septation mechanisms that confer...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $230,313 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a genome-wide CRISPR screening platform in diploid Candida albicans for identifying mechanisms of antifungal resistance. The project will create tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, then apply these tools to perform genome-wide screening to...
- The National Institute of Allergy and Infectious Diseases awarded East Tennessee State University $142,785 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize neutrophil swarming responses to fungal pathogens relevant to diabetes mellitus. The research addresses invasive fungal infections caused by Candida, Aspergillus, and Zygomycetes species that pose serious public health threats in immunocompromised patients, including those with...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $231,000 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate HIV integrase strand transfer inhibitors as potential antifungal agents against Cryptococcus species. The research examines whether multiple integrase inhibitors—including bictegravir, dolutegravir, raltegravir, elvitegravir, and cabotegravir—inhibit cryptococcal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut $251,062 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antifolate compounds with broad-spectrum antifungal activity targeting invasive fungal infections. The funded research addresses unmet clinical needs in treating opportunistic and emerging fungal pathogens, including Candida auris, Candida albicans, Candida glabrata, Cryptococcus neoformans,...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...
- The National Institute of Allergy and Infectious Diseases awarded Clemson University $418,378 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of long-noncoding RNA AFU-182 in regulating fungal tolerance to azole antifungal drugs in Aspergillus fumigatus. The research addresses rising invasive infections caused by the saprophytic mold A. fumigatus and the unclear mechanisms of fungal adaptation to azole drugs. The project will...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Health Science Center at Houston $429,000 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct spatial analysis of gene expression in fungal infections. The research applies spatial transcriptional analysis to host-pathogen interactions, focusing on fungal infection biology. The project develops and expands a laboratory method that enables visualization...
- The National Institute of Allergy and Infectious Diseases awarded the University of Toledo $216,770 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a new class of covalent antifungal drug candidates. The award, designated R21AI195315, funds research through May 31, 2028, and is performed at the University of Toledo in Ottawa Hills, Ohio. The project aims to optimize and test novel covalent enzyme inactivators targeting a microbial pathway...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc., $228,000 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize pan-fungal monoclonal antibodies targeting Aspergillus. The award funds research to develop and evaluate a panel of anti-NXT-2 monoclonal antibodies (MABs) as prophylactic, priority, or adjunctive therapies for invasive aspergillosis and other...